Medtronic Neurovascular Makes Debut at APSCVIR 2026 with Comprehensive Peripheral Vascular Solutions

At this conference, Medtronic did not merely present individual products; instead, it centered on an integrated “materials + access” solution to build a comprehensive vascular embolization system:

This combination not only covers the complete pathway from superselection to embolization shaping, but also takes into account accessibility and operational stability under complex vascular anatomy, achieving full-process optimization from "placement" to "occlusion." From the product portfolio, it is evident that Medtronic is replicating its mature neurointerventional technology system in the peripheral field, providing solutions that can be standardized for widespread adoption.

Centering on the application of Onyx™ in peripheral vessels, this conference will highlight three major sections:

"Application of Non-Adhesive Liquid Embolic Agents in Peripheral Vessels"

• The content will systematically review the evidence-based data and indications for Onyx™ in portal hypertension, endoleaks, hemorrhage, and venous diseases.

Onyx™ Hands-on Workshop

• Through live procedural demonstrations, intuitively experience the lava-like solidification and precipitation process of Onyx™, facilitating the transition from “knowing” to “doing” and enhancing clinical translation capabilities.

• Centralized Display:Onyx™ Application Pathways in Various Peripheral Diseases: Synergistic Strategies for Embolic Materials and Access Systems, Typical Cases, and Comprehensive Solutions—Upgrading from a Single Product to a Replicable Clinical Solution Model.

Its advantages are particularly prominent in complex peripheral lesions:

More importantly, Onyx™ has accumulated robust evidence-based data in clinical scenarios involving peripheral adjunctive embolization, structural vascular lesions, and peripheral hemorrhage.

• an additional 24% reduction in rebleeding rate;

• Further reduces the incidence of hepatic encephalopathy by 16%;

• Reduces the rate of subsequent decompensation by an additional 55%.

• Reduces the risk of capsule enlargement by an additional 61%²。

• Clinical success rate as high as 93.3%³。

• Sustained Pain Improvement at 12 Months (P=0.001)⁴。